PDCD1 and non-small cell lung carcinoma: To fill this knowledge gap, this multicenter retrospective analysis, involved 1266 patients diagnosed with advanced NSCLC, treated with PD‐1 or PD‐L1 inhibitors across institutions in the Sichuan, Shandong, and Guangdong provinces of China.